Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

131 ARTÍCULOS , VIENDO DEL 16 AL 30

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ.

Exp Gerontol. 2010 Jan;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub 2009 Oct 22.

Origins, controversies and recent developments of the MCI construct

Gainotti G.

Curr Alzheimer Res. 2010 May;7(3):271-9. doi: 10.2174/156720510791050858.

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease

Schmand B, Huizenga HM, van Gool WA.

Psychol Med. 2010 Jan;40(1):135-45. doi: 10.1017/S0033291709991516. Epub 2009 Oct 29.

Protein kinase C as a peripheral biomarker for Alzheimer's disease

de Barry J, Liégeois CM, Janoshazi A.

Exp Gerontol. 2010 Jan;45(1):64-9. doi: 10.1016/j.exger.2009.10.015. Epub 2009 Nov 4.

Editorial to biomarkers of Alzheimers disease and dementia in cerebrospinal fluid and blood

Humpel C.

Exp Gerontol. 2010 Jan;45(1):1. doi: 10.1016/j.exger.2009.11.001. Epub 2009 Nov 6.

Decreased C-reactive protein levels in Alzheimer disease

O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R.

J Geriatr Psychiatry Neurol. 2010 Mar;23(1):49-53. doi: 10.1177/0891988709351832. Epub 2009 Nov 20.

Sleep and biomarkers of atherosclerosis in elderly Alzheimer caregivers and controls

von Känel R, Ancoli-Israel S, Dimsdale JE, Mills PJ, Mausbach BT, Ziegler MG, Patterson TL, Grant I.

Gerontology. 2010;56(1):41-50. doi: 10.1159/000264654. Epub 2009 Dec 3.

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ.

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8.

Genetic risk factors and candidate biomarkers for Alzheimer's disease

Scapagnini G, Caruso C, Vasto S, Pascale A, Romeo L, D'Agata V, Intrieri M, Sapere N, Li Volti G.

Front Biosci (Schol Ed). 2010 Jan 1;2(2):616-22. doi: 10.2741/s89.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW.

Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.

Coronary artery bypass surgery provokes Alzheimer's disease-like changes in the cerebrospinal fluid

Palotás A, Reis HJ, Bogáts G, Babik B, Racsmány M, Engvau L, Kecskeméti E, Juhász A, Vieira LB, Teixeira AL, Mukhamedyarovi MA, Rizvanov AA, Yalvaç ME, Guimarães MM, Ferreira CN, Zefirov AL, Kiyasov AP, Wang L, Janka Z, Kálmán J.

J Alzheimers Dis. 2010;21(4):1153-64. doi: 10.3233/jad-2010-100702.

Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease

Iuliano L, Monticolo R, Straface G, Spoletini I, Gianni W, Caltagirone C, Bossù P, Spalletta G.

J Alzheimers Dis. 2010;21(4):1383-92. doi: 10.3233/jad-2010-100780.

Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients

Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, Leyhe T, Stellos K.

J Alzheimers Dis. 2010;21(4):1263-9. doi: 10.3233/jad-2010-100510.

Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men

Chu LW, Tam S, Wong RL, Yik PY, Song Y, Cheung BM, Morley JE, Lam KS.

J Alzheimers Dis. 2010;21(4):1335-45. doi: 10.3233/jad-2010-100027.

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O.

J Alzheimers Dis. 2010;21(4):1119-28. doi: 10.3233/jad-2010-100207.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias